Reversible Ductus Arteriosus Constriction due to Maternal Indomethacin after Fetal Intervention for Hypoplastic Left Heart Syndrome with Intact/Restrictive Atrial Septum

Department of Cardiology, Children's Hospital Boston, and Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
Fetal Diagnosis and Therapy (Impact Factor: 2.3). 12/2009; 27(1):40-5. DOI: 10.1159/000268290
Source: PubMed

ABSTRACT Fetal cardiac intervention (FCI) has been performed at our center in selected fetuses with complex congenital heart disease since 2000. Most interventions are performed in fetuses with a ductus arteriosus (DA)-dependent circulation. Indomethacin promotes closure of the DA in newborns and in fetal life, a potentially life threatening complication in fetuses with ductus-dependent congenital heart disease.
We reviewed our experience with FCI with a focus on the frequency, features, and clinical course of ductal constriction. Fetuses undergoing FCI receive comprehensive pre- and postoperative cardiac and cerebral ultrasound evaluation, approximately 24 hours before and after the procedure, including imaging of DA flow and Doppler assessment of the umbilical artery and vein, ductus venosus, and, since 2004, the middle cerebral artery.
Among 113 fetuses that underwent FCI, 24 of which were older than 28 0/7 weeks gestation, 2 were found to have DA constriction due to indomethacin therapy within 24 hours of intervention. Both of these were 30-week fetuses with hypoplastic left heart syndrome and restrictive or intact atrial septum. The DA was stenotic by spectral and color Doppler, and middle cerebral and umbilical artery pulsatility indexes were depressed. After discontinuation of indomethacin, the Doppler indices improved or normalized.
Close echocardiographic monitoring of fetal Doppler flow velocities is very important after fetal intervention and indomethacin treatment, as the consequences of DA constriction in a fetus with hypoplastic left heart syndrome are potentially lethal. Sonographic evaluation should include measurement of cerebral and umbilical arterial flow velocities as well as color and spectral Doppler interrogation of the DA.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Fetal circulation has characteristic features, being morphologically and functionally different from extrauterine circulation. The ductus arteriosus plays a fundamental role in directing the blood flow to fetal inferior body parts. Basically, the ductus arteriosus directs 80-85% of the right ventricular output arising from the superior vena cava, coronary sinus, and a small part from the inferior vena cava to descending aorta. Its histological structure is made up predominantly by a thick muscular layer, differently from the aorta and the pulmonary artery, which increases with gestational age. The fibers have a circumferential orientation, especially at the external layers, facilitating and making effective ductal constriction. These factors may generate lumen alterations which may cause fetal and neonatal complications, such as heart failure, hydrops, neonatal pulmonary hypertension, and even death. Classically, maternal administration of indomethacin and/or other antiinflammatory drugs interfere in prostaglandins metabolism, causing ductal constriction. However, many cases of fetal ductal constriction, as well as of persistent neonatal pulmonary artery hypertension, remain without an established etiology, being referred as "idiopathic." In recent years, a growing body of evidence has shown that herbs, fruits, nuts, and a wide diversity of substances commonly used in daily diets have definitive effects upon the metabolic pathway of inflammation, with consequent inhibition of prostaglandins synthesis. This antiinflammatory action, especially of polyphenols, when ingested during the third trimester of pregnancy, may influence the dynamics of fetal ductus arteriosus flow. The goal of this review is to present these new observations and findings, which may influence dietary orientation during pregnancy. Birth Defects Research (Part C) 99:256-274, 2013. © 2013 Wiley Periodicals, Inc.
    Birth Defects Research Part C Embryo Today Reviews 12/2013; 99(4):256-74. DOI:10.1002/bdrc.21051 · 4.44 Impact Factor
    This article is viewable in ResearchGate's enriched format
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: Endocardial fibroelastosis (EFE) is a unique form of fibrosis which forms a de novo subendocardial tissue layer encapsulating the myocardium and stunting its growth, and which is typically associated with congenital heart diseases of heterogeneous origin, such as hypoplastic left heart syndrome. Relevance of EFE was only recently highlighted through establishment of staged biventricular repair surgery in HLHS infant patients, where surgical removal of EFE tissue has resulted in improvement in the restrictive physiology leading to growth of the left ventricle in parallel with somatic growth. However, pathomechanisms underlying EFE formation are still scarce and specific therapeutic targets are not yet known. Objective: Here we aimed to investigate the cellular origins of EFE tissue and to gain insights into underlying molecular mechanisms to ultimately develop novel therapeutic strategies. Methods and Results: By utilizing a novel EFE model of heterotopic transplantation of hearts from newborn reporter mice and by analyzing human EFE tissue, we demonstrate for the first time that fibrogenic cells within EFE tissue originate from endocardial endothelial cells via aberrant endothelial mesenchymal transition (EndMT). We further demonstrate that such aberrant EndMT involving endocardial endothelial cells is caused by dysregulated TGFβ/BMP signaling and that this imbalance is at least in part caused by aberrant promoter methylation and subsequent transcriptional suppression of BMP5 and BMP7. Finally, we provide evidence that supplementation of exogenous recombinant BMP7 effectively ameliorates EndMT and experimental EFE in rats. Conclusions: In summary our data point to aberrant EndMT as a common denominator of infant EFE development in heterogeneous, congenital heart diseases, and to BMP7 as an effective treatment for EFE and its restriction of heart growth.
    Circulation Research 01/2015; DOI:10.1161/CIRCRESAHA.116.305629 · 11.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This is the first report of the use of veno-venous extracorporeal membrane oxygenation in a neonate with severe Ebstein's anomaly. The report suggests the use of veno-venous extracorporeal membrane oxygenation in the immediate neonatal period may be a useful therapy in severe Ebstein's anomaly. By providing adequate oxygenation independent of the patient's native pulmonary blood flow, veno-venous extracorporeal membrane oxygenation allows the pulmonary vascular resistance to decrease and may promote right ventricular recovery.
    Annals of Pediatric Cardiology 01/2015; 8(1):67-70. DOI:10.4103/0974-2069.149527


Available from
May 16, 2014